Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | BROCADE3: veliparib with carboplatin/paclitaxel in HER2-/BRCA+ advanced breast cancer

Véronique Dieras • 27 Sep 2019
ESMO 2019
Breast Cancer Carboplatin Paclitaxel Veliparib
BROCADE3

Véronique Dieras, MD, Eugène Marquis Center, Rennes, France, discusses the BROCADE3 trial (NCT02163694). This trial is investigating the efficacy and tolerability of veliparib vs. a placebo in combination with carboplatin and paclitaxel in HER2-negative metastatic or locally advanced, unresectable, BRCA-associated breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Véronique Dieras

How are ADCs & CDK inhibitors reshaping metastatic breast cancer treatment?
2:29
How are ADCs & CDK inhibitors reshaping metastatic breast cancer treatment?
Véronique Dieras • 26 Oct 2026
T-DXd and pertuzumab redefines HER2+ metastatic breast cancer treatment
2:10
T-DXd and pertuzumab redefines HER2+ metastatic breast cancer treatment
Véronique Dieras • 26 Oct 2026
HER2CLIMB-05: quality of life with tucatinib maintenance in HER2+ breast cancer
3:33
HER2CLIMB-05: quality of life with tucatinib maintenance in HER2+ breast cancer
Véronique Dieras • 26 Oct 2026
TNBC treatment: platinum-based therapy and PARP inhibition
0:58
TNBC treatment: platinum-based therapy and PARP inhibition
Véronique Dieras • 27 Sep 2019

Related Videos

FINER: overall survival with ipatasertib & fulvestrant in ER+/HER2- breast cancer
1:46
FINER: overall survival with ipatasertib & fulvestrant in ER+/HER2- breast cancer
Andrew Redfern • 24 Oct 2026
Treatment options for ER+ breast cancer after CDK4/6 inhibitors
2:27
Treatment options for ER+ breast cancer after CDK4/6 inhibitors
Andrew Redfern • 24 Oct 2026
Phase I trial of intrathecal cDC1s in breast cancer leptomeningeal disease
2:10
Phase I trial of intrathecal cDC1s in breast cancer leptomeningeal disease
Peter Forsyth • 25 Oct 2026
GIM3 FATA: aromatase inhibitor schedule and choice in early breast cancer
5:03
GIM3 FATA: aromatase inhibitor schedule and choice in early breast cancer
Pietro De Placido • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals